Articles citing this paper
Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia
Ingrid A. Cox
A B , Barbara de Graaff A B , Tamera J. Corte B C D , Ian Glaspole B E F , Daniel C. Chambers B G H , Yuben Moodley B I J K , Alan Teoh B D , E. Haydn Walters A B * and Andrew J. Palmer A B L M *
A Menzies Institute for Medical Research, The University of Tasmania, Hobart, Tas., Australia. Email: ingrid.cox@utas.edu.au; barbara.degraaff@utas.edu.au; haydn.walters@utas.edu.au
B National Health and Medical Research Council (NHMRC) Centre of Research Excellence for Pulmonary Fibrosis, Camperdown, NSW, Australia. Email: tamera.corte@sydney.edu.au; ian.glaspole@monash.edu; alan.teoh@health.nsw.gov.au
C Central Clinical School, The University of Sydney, Camperdown, NSW, Australia.
D Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
E Interstitial Lung Disease Clinic, Alfred Hospital, Melbourne, Vic., Australia.
F Central Clinical School, Monash University, Melbourne, Vic., Australia.
G School of Clinical Medicine, The University of Queensland, Brisbane, Qld, Australia. Email: daniel.chambers@health.qld.gov.au
H Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Qld, Australia.
I Faculty of Health and Medical Sciences, The University of Western Australia, Perth, WA, Australia. Email: yuben.moodley@uwa.edu.au
J Institute of Respiratory Health, The University of Western Australia, Perth, WA, Australia.
K Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, WA, Australia.
L Centre for Health Policy, School of Population and Global Health, The University of Melbourne, Melbourne, Vic., Australia.
M Corresponding author. Email: andrew.palmer@utas.edu.au
Australian Health Review 45(6) 718-727 https://doi.org/10.1071/AH20337
Submitted: 25 November 2020 Accepted: 10 March 2021 Published: 28 October 2021
